Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are collecting and evaluating data on various Abbott vascular medical devices used in clinical procedures. This prospective, non-randomized, open-label, multi-center registry aims to confirm the safety and performance of these devices over their expected lifetime. The study also focuses on monitoring risks, detecting new risks based on real evidence, ensuring the benefit-risk balance remains acceptable, and identifying any misuse or off-label use to verify appropriate device use. Participants receive one or more Abbott vascular devices, such as coronary and peripheral stents, pacing catheters, vascular plugs, measurement and imaging tools including FFR and OCT, peripheral and coronary dilatation catheters, guidewires, vessel closure or compression devices, and vascular access introducers. The study covers multiple device types used during vascular procedures performed as part of routine clinical care. During the study, researchers collect clinical data throughout and after the procedures, monitoring outcomes like death, myocardial infarction, target lesion revascularization, amputations, procedural complications, device success, and safety issues. Follow-up assessments occur at procedure time, 30 days, and 12 months to evaluate these outcomes. Participants are followed according to the specified schedule, which may include data collection on clinical events and device performance over time.
Actively Recruiting
Researchers are studying how gastrointestinal GI symptoms develop in patients with anorexia nervosa AN and bulimia nervosa BN during multi-week inpatient weight rehabilitation. The study focuses on how different dietary approachesflexitarian, vegetarian, or veganrelate to changes in GI symptoms throughout treatment. It also examines how weight gain, clinical factors, psychological status, and demographic details influence GI symptoms over time. The main goal is to understand symptom changes from admission to discharge using a GI symptom severity score, with analyses done separately for AN and BN groups. Participants are patients with AN or BN undergoing standard inpatient treatment aimed at weight rehabilitation and normalizing eating behavior at a specialized eating disorder center. During their stay, patients follow usual diagnostic and treatment procedures while detailed data on dietary intake and GI symptoms are collected. GI symptoms are assessed upon admission, weekly during hospitalization, and at discharge. The study tracks other clinical measurements such as body weight, body composition, and psychological assessments. Participants complete weekly questionnaires about GI symptoms as part of their routine care. Researchers collect body weight, composition, and various psychological survey data at admission and discharge, with some tests repeated weekly. Laboratory tests including blood counts and metabolic panels are also gathered regularly. The primary outcome measures the change in GI symptoms from admission to discharge, while secondary analyses evaluate symptoms over time, dietary impact, and clinical predictors. The study plans to enroll about 150 AN and 35-40 BN patients, with total participation spanning their inpatient stay.
Actively Recruiting
The VISTA Nova Study focuses on patients with aortic stenosis who are undergoing transcatheter aortic valve replacement TAVR. The goal is to assess the safety, performance, and long-term durability of the Navitor valve in a real-world setting. This observational study evaluates how well the device works and its impact on patient outcomes over time. Participants will receive the Navitor Transcatheter Aortic Valve using the FlexNav delivery system and the Navitor Loading System. The Navitor valve comes in five sizes to fit annulus diameters from 19 mm to 30 mm, and the delivery and loading systems are available in two sizes each. The procedure follows approved indications and involves specialized equipment to implant the valve. During the study, participants will be monitored at scheduled follow-up visits after their TAVI procedure to track outcomes such as overall survival and valve leakage. The primary outcomes measured include all-cause mortality and the presence of moderate or greater paravalvular leak at 30 days post-procedure. Participants are expected to return for all required follow-up visits to help researchers evaluate the valves long-term safety and effectiveness, with the study continuing through 2032.